David D. O'Toole - 02 Mar 2023 Form 4 Insider Report for OPIANT PHARMACEUTICALS, INC.

Reporting relationship: Chief Financial Officer
Issuer ticker: N/A
Reported as of: 02 Mar 2023
Net transaction value: -$724,960
SEC form: 4
Accepted by SEC: 03 Mar 2023, 07:57:07 UTC
Prior SEC filing: 31 Jan 2023
Next SEC filing: 16 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ David D. O'Toole

Key filing fact

David D. O'Toole filed Form 4 for OPIANT PHARMACEUTICALS, INC. on 03 Mar 2023.

Key facts

This page summarizes David D. O'Toole's Form 4 filing for OPIANT PHARMACEUTICALS, INC..
7 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 03 Mar 2023, 07:57.

Change

Previous filing in this sequence was filed on 31 Jan 2023.
Current net transaction value: -$724,960.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OPNT transaction

Common Stock

Disposed to Issuer

Transaction value: $450,240
Shares: -22,512
Change %: -66%
Price: $20.00
Shares after: 11,736
Date: 02 Mar 2023
Ownership: Direct
Footnotes: F1

OPNT transaction

Common Stock

Disposed to Issuer

Transaction value: $234,720
Shares: -11,736
Change %: -100%
Price: $20.00
Shares after: 0
Date: 02 Mar 2023
Ownership: Direct
Footnotes: F2

OPNT transaction

Common Stock

Award

Transaction value: $0
Shares: +2,000
Change %
Price: $0.000000
Shares after: 2,000
Date: 02 Mar 2023
Ownership: Direct
Footnotes: F3

OPNT transaction

Common Stock

Disposed to Issuer

Transaction value: $40,000
Shares: -2,000
Change %: -100%
Price: $20.00
Shares after: 0
Date: 02 Mar 2023
Ownership: Direct
Footnotes: F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OPNT transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value: $0
Shares: -33,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Mar 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 33,000
Exercise price: $13.61
Footnotes: F5

OPNT transaction Derivative

Common Stock

Disposed to Issuer

Transaction value: $0
Shares: -8,250
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Mar 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,250
Exercise price: $13.60
Footnotes: F5

OPNT transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value: $0
Shares: -10,750
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Mar 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,750
Exercise price: $12.15
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

David D. O'Toole is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 5 footnotes

Footnote F1

Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Indivior Inc., and Olive Acquisition Subsidiary, Inc., dated as of November 13, 2022 (the "Merger Agreement"), in exchange for a cash payment of $20.00 per share without interest thereon (the "Merger Consideration").

Footnote F2

Disposed of pursuant to the Merger Agreement, in exchange for the Merger Consideration. The number of shares disposed of reflects 11,736 shares of Common Stock upon the acceleration of vesting of restricted stock units in accordance with the Merger Agreement.

Footnote F3

2,000 shares are represented by performance stock units ("PSUs"), the vesting of which accelerated in accordance with the Merger Agreement. Each PSU represents the Reporting Person's right to receive one share of Common Stock of Issuer.

Footnote F4

Disposed of pursuant the Merger Agreement, in exchange for the Merger Consideration. The number of shares disposed of reflects 2,000 shares of Common Stock upon the acceleration of vesting of performance stock units in accordance with the Merger Agreement.

Footnote F5

The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares.